Myasthenia gravis (MG) is an autoantibody mediated autoimmune disease of the neuromuscular junction (NMJ), and anti-muscle-specific receptor tyrosine kinase (MuSK) antibody-related MG (MuSK-MG) covers 5%-8% of all MG patients. MuSK-MG is a life threatening condition, characterized with early bulbar, neck, and respiratory muscle weakness. MuSK-MG patients have poor response to standard therapies, known as drug-resistant patients. Rituximab (RTX) is a monoclonal antibody that targets the CD20 antigen on B cells. At present, most studies have described clinical improvement and immunosuppressant dose reduction following RTX treatment of refractory MG patients, especially for MuSK-MG patients.
李婷, 杨丽. 利妥昔单抗在抗MuSK抗体阳性重症肌无力中的应用进展[J]. 中国现代神经疾病杂志, 2020, 20(1): 48-54.
LI Ting, YANG Li. Progress in rituximab for anti-MuSK antibody-related myasthenia gravis. Chinese Journal of Contemporary Neurology and Neurosurgery, 2020, 20(1): 48-54.
Salles G, Barrett M, Foà R, Maurer J, O'Brien S, Valente N, Wenger M, Maloney DG. Rituximab in B-cell hematologic malignancies:a review of 20 years of clinical experience[J]. Adv Ther, 2017, 34:2232-2273.
[3]
Einarsson JT, Evert M, Geborek P, Saxne T, Lundgren M, Kapetanovic MC. Rituximab in clinical practice:dosage, drug adherence, Ig levels, infections, and drug antibodies[J]. Clin Rheumatol, 2017, 36:2743-2750.
[4]
Hui-Yuen JS, Nguyen SC, Askanase AD. Targeted B cell therapies in the treatment of adult and pediatric systemic lupus erythematosus[J]. Lupus, 2016, 25:1086-1096.
[5]
Grace RF, Shimano KA, Bhat R, Neunert C, Bussel JB, Klaassen RJ, Lambert MP, Rothman JA, Breakey VR, Hege K, Bennett CM, Rose MJ, Haley KM, Buchanan GR, Geddis A, Lorenzana A, Jeng M, Pastore YD, Crary SE, Neier M, Neufeld EJ, Neu N, Forbes PW, Despotovic JM. Second-line treatments in children with immune thrombocytopenia:effect on platelet count and patient-centered outcomes[J]. Am J Hematol, 2019, 94:741-750.
[6]
Dalakas MC. Immunotherapy in myasthenia gravis in the era of biologics[J]. Nat Rev Neurol, 2019, 15:113-124.
[7]
Robeson KR, Kumar A, Keung B, DiCapua DB, Grodinsky E, Patwa HS, Stathopoulos PA, Goldstein JM, O'Connor KC, Nowak RJ. Durability of the rituximab response in acetylcholine receptor autoantibody-positive myasthenia gravis[J]. JAMA Neurol, 2017, 74:60-66.
[8]
Yi JS, Guptill JT, Stathopoulos P, Nowak RJ, O'Connor KC. B cells in the pathophysiology of myasthenia gravis[J]. Muscle Nerve, 2018, 57:172-184.
[9]
Phillips WD, Vincent A. Pathogenesis of myasthenia gravis:update on disease types, models, and mechanisms[J]. F1000Res, 2016, 5 pii:1513.
[10]
Koneczny I, Stevens JA, De Rosa A, Huda S, Huijbers MG, Saxena A, Maestri M, Lazaridis K, Zisimopoulou P, Tzartos S, Verschuuren J, van der Maarel SM, van Damme P, De Baets MH, Molenaar PC, Vincent A, Ricciardi R, Martinez-Martinez P, Losen M. IgG4 autoantibodies against muscle-specific kinase undergo Fab-arm exchange in myasthenia gravis patients[J]. J Autoimmun, 2017, 77:104-115.
[11]
Stathopoulos P, Kumar A, Heiden JA, Pascual-Goñi E, Nowak RJ, O'Connor KC. Mechanisms underlying B cell immune dysregulation and autoantibody production in MuSK myasthenia gravis[J]. Ann NY Acad Sci, 2018, 1412:154-165.
[12]
Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR, Barohn RJ, Dimachkie MM, Ciafaloni E, Broering TJ, Vigneault F, Nowak RJ, Kleinstein SH, O'Connor KC. Dysregulation of b cell repertoire formation in myasthenia gravis patients revealed through deep sequencing[J]. J Immunol, 2017, 198:1460-1473.
[13]
Ramwadhdoebe TH, van Baarsen LG, Boumans MJ, Bruijnen ST, Safy M, Berger FH, Semmelink JF, van der Laken CJ, Gerlag DM, Thurlings RM, Tak PP. Effect of rituximab treatment on T and B cell subsets in lymph node biopsies of patients with rheumatoid arthritis[J]. Rheumatology (Oxford), 2019, 58:1075-1085.
[14]
Illa I, Diaz-Manera J, Rojas-Garcia R, Pradas J, Rey A, Blesa R, Juarez C, Gallardo E. Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis patients[J]. J Neuroimmunol, 2008, 201/202:90-94.
[15]
Blum S, Gillis D, Brown H, Boyle R, Henderson R, Heyworth-Smith D, Hogan P, Kubler P, Lander C, Limberg N, Pillans P, Prain K, Staples C, Walsh M, McCombe P, Wong R. Use and monitoring of low dose rituximab in myasthenia gravis[J]. J Neurol Neurosurg Psychiatry, 2011, 82:659-663.
[16]
Díaz-Manera J, Martínez-Hernández E, Querol L, Klooster R, Rojas-García R, Suárez-Calvet X, Muñ oz-Blanco JL, Mazia C, Straasheijm KR, Gallardo E, Juárez C, Verschuuren JJ, Illa I. Long-lasting treatment effect of rituximab in MuSK myasthenia[J]. Neurology, 2012, 78:189-193.
[17]
Huang H, Benoist C, Mathis D. Rituximab specifically depletes short-lived autoreactive plasma cells in a mouse model of inflammatory arthritis[J]. Proc Natl Acad Sci USA, 2010, 107:4658-4663.
[18]
Winter O, Dame C, Jundt F, Hiepe F. Pathogenic long-lived plasma cells their survival niches in autoimmunity, malignancy, and allergy[J]. J Immunol, 2012, 189:5105-5111.
Anderson D, Phan C, Johnston WS, Siddiqi ZA. Rituximab in refractory myasthenia gravis:a prospective, open-label study with long-term follow-up[J]. Ann Clin Transl Neurol, 2016, 3:552-555.
[21]
Afanasiev V, Demeret S, Bolgert F, Eymard B, Laforêt P, Benveniste O. Resistant myasthenia gravis and rituximab:a monocentric retrospective study of 28 patients[J]. Neuromuscul Disord, 2017, 27:251-258.
[22]
Hehir MK, Hobson-Webb LD, Benatar M, Barnett C, Silvestri NJ, Howard JF Jr, Howard D, Visser A, Crum BA, Nowak R, Beekman R, Kumar A, Ruzhansky K, Chen IA, Pulley MT, LaBoy SM, Fellman MA, Greene SM, Pasnoor M, Burns TM. Rituximab as treatment for anti-MuSK myasthenia gravis:multicenter blinded prospective review[J]. Neurology, 2017, 89:1069-1077.
[23]
Beecher G, Anderson D, Siddiqi ZA. Rituximab in refractory myasthenia gravis:extended prospective study results[J]. Muscle Nerve, 2018, 58:452-455.
[24]
Chan F, Swayne A, Gillis D, Walsh M, Henderson RD, Mc Combe PA, Wong RC, Blum S. Long-term follow-up of patients with myasthenia gravis treated with low-dose rituximab[J]. J Neurol Neurosurg Psychiatry, 2019, 90:955-956.
[25]
Topakian R, Zimprich F, Iglseder S, Embacher N, Guger M, Stieglbauer K, Langenscheidt D, Rath J, Quasthoff S, Simschitz P, Wanschitz J, Windisch D, Müller P, Oel D, Schustereder G, Einsiedler S, Eggers C, L öscher W. High efficacy of rituximab for myasthenia gravis:a comprehensive nationwide study in Austria[J]. J Neurol, 2019, 266:699-706.
[26]
Kanth KM, Solorzano GE, Goldman MD. PML in a patient with myasthenia gravis treated with multiple immunosuppressing agents[J]. Neurol Clin Pract, 2016, 6:E17-19.
[27]
Strand V, Balsa A, Al-Saleh J, Barile-Fabris L, Horiuchi T, Takeuchi T, Lula S, Hawes C, Kola B, Marshall L. Immunogenicity of biologics in chronic in flammatory diseases:a systematic review[J]. BioDrugs, 2017, 31:299-316.
[28]
Md Yusof MY, Shaw D, El-Sherbiny YM, Dunn E, Rawstron AC, Emery P, Vital EM. Predicting and managing primary and secondary non-response to rituximab using B-cell biomarkers in systemic lupus erythematosus[J]. Ann Rheum Dis, 2017, 76:1829-1836.
[29]
Dunn N, Juto A, Ryner M, Manouchehrinia A, Piccoli L, Fink K, Piehl F, Fogdell-Hahn A. Rituximab in multiple sclerosis:frequency and clinical relevance of anti-drug antibodies[J]. Mult Scler, 2018, 24:1224-1233.
[30]
Li T, Zhang LJ, Zhang QX, Yang CS, Zhang C, Li YJ, Shi FD, Yang L. Anti-Rituximab antibody in patients with NMOSDs treated with low dose Rituximab[J]. J Neuroimmunol, 2018, 316:107-111.
